We are pleased to share that adults living in Scotland who have IgA nephropathy (IgAN) will now, in certain circumstances, be able to access a new treatment on the NHS following a decision made today by the Scottish Medicines Consortium (SMC).
Kidney Care UK submitted evidence to the SMC of what sparsentan (Filspari®) might mean to people with IgAN. This decision means that individuals whose treatment for IgAN has not responded adequately to current standard care may now be considered for this treatment.
Kidney Care UK welcome this decision and the availability of a new treatment for IgAN, for which there are very limited treatment options, in Scotland.
For some this drug will be a gateway to a transplant; managing the disease will enable them to receive a kidney but also to potentially prevent its recurrence in a transplanted kidney, thus providing some physical and mental health relief. A big thank you to everyone who gives us their comments and helps us bring forward why and how new treatments can improve our lives. You are making a difference.Fiona Loud, Policy Director, Kidney Care UK
We recommend speaking with your doctor if you would like to know more about whether the treatment might be right for you, once it becomes available.